学歴 【 表示 ／ 非表示 】

学歴 【 表示 ／ 非表示 】

• 　

  -

  1987年

  筑波大学   医学部  

• 　

  -

  1987年

  筑波大学   Faculty of Medicine  

学位 【 表示 ／ 非表示 】

学位 【 表示 ／ 非表示 】

• 筑波大学   博士(医学)

所属学協会 【 表示 ／ 非表示 】

所属学協会 【 表示 ／ 非表示 】

• 　

  　

  　

  日本癌治療学会

• 　

  　

  　

  日本医療情報学会

• 　

  　

  　

  日本臨床疫学会

• 　

  　

  　

  日本臨床試験学会

• 　

  　

  　

  日本薬剤疫学会

全件表示 >>

研究分野 【 表示 ／ 非表示 】

研究分野 【 表示 ／ 非表示 】

• ライフサイエンス   泌尿器科学  

• ライフサイエンス   薬理学  

• ライフサイエンス   衛生学、公衆衛生学分野：実験系を含まない  

• ライフサイエンス   衛生学、公衆衛生学分野：実験系を含む  

• ライフサイエンス   医療管理学、医療系社会学  

researchmapの所属 【 表示 ／ 非表示 】

researchmapの所属 【 表示 ／ 非表示 】

• 札幌医科大学   医療統計・データ管理学   教授  

論文 【 表示 ／ 非表示 】

論文 【 表示 ／ 非表示 】

• Summary of the Clinical Practice Guidelines for Upper Tract Urothelial Carcinoma 2023 by the Japanese Urological Association.

  Kazuyuki Mori, Shingo Hatakeyama, Hideki Enokida, Hideaki Miyake, Eiji Kikuchi, Hiroyuki Nishiyama, Tomohiko Ichikawa, Takao Kamai, Yasushi Kaji, Haruki Kume, Tsunenori Kondo, Hideyasu Matsuyama, Naoya Masumori, Akihiro Kawauchi, Atsushi Takenaka, Hirotsugu Uemura, Masatoshi Eto, Norio Nonomura, Yasuhisa Fujii, Shiro Hinotsu, Chikara Ohyama

  International journal of urology : official journal of the Japanese Urological Association   31 ( 3 ) 194 - 207  2024年03月  [国際誌]

  　概要を見る

  This article is an English translation of the Clinical Practice Guidelines for Upper Tract Urothelial Carcinoma (2nd edition) published in June 2023. The Japanese Urological Association's (JUA) Guidelines Committee on Upper Tract Urothelial Carcinoma (UTUC) created a 2023 update guideline to support clinicians' current evidence-based management of UTUC and to incorporate its recommendations into clinical practice. The new guideline adhered as closely as possible to the Minds Manual for Guideline Development 2020 ver. 3.0. Findings related to epidemiological, pathological, diagnosis, treatment, and follow-up were reviewed. In addition, seven clinical questions (CQs) were set to determine the grade of recommendation and level of evidence. Preconceptions and biases were removed from the preparation process, the overall evidence was evaluated appropriately, and recommendations were made after fully considering the balance between benefits and harms. Although the evidence is still insufficient to be taken up as a CQ, the latest important information is described in seven columns, and clinical issues that should be resolved in the future related to the CQ are described as recommendations for tomorrow. We hope that these guidelines will help medical professionals, patients, and their families involved in the treatment of UTUC in their decision-making, and hope that a critical review of these guidelines will lead to further refinements in the next edition.

  DOI PubMed

• A feasibility study of provider-level implementation strategies to improve access to colorectal cancer screening for patients with schizophrenia: ACCESS2 (N-EQUITY 2104) trial.

  Masaki Fujiwara, Yuto Yamada, Tsuyoshi Etoh, Taichi Shimazu, Masafumi Kodama, Norihito Yamada, Takahiro Asada, Shigeo Horii, Takafumi Kobayashi, Teruo Hayashi, Yoshitaka Ehara, Kenji Fukuda, Keita Harada, Maiko Fujimori, Miyuki Odawara, Hirokazu Takahashi, Shiro Hinotsu, Naoki Nakaya, Yosuke Uchitomi, Masatoshi Inagaki

  Implementation science communications   5 ( 1 ) 2 - 2  2024年01月  [査読有り]  [国際誌]

  　概要を見る

  BACKGROUND: People with schizophrenia have a lower colorectal screening rate than the general population. A previous study reported an intervention using case management to encourage colorectal cancer screening for patients with schizophrenia in psychiatric outpatient settings. In this feasibility study, we developed provider-level implementation strategies and evaluated the feasibility of conducting a definitive trial in terms of the penetration of the intervention assessed at the patient level. Additionally, we examined the fidelity of strategies to implement the intervention at the provider level in a routine clinical psychiatric setting. METHODS: This was a multicenter, single-arm feasibility study with medical staff at psychiatric hospitals in Japan. The provider-level implementation strategies developed in this study included three key elements (organizing an implementation team appointed by the facility director, interactive assistance using a clear guide that outlines who in the hospital should do what, and developing accessible educational materials) to overcome major barriers to implementation of the intervention and four additional elements (progress monitoring, joint meetings and information sharing among participating sites, adaptation of encouragement methods to specific contexts, and education of on-site staff), with reference to the elements identified in the Expert Recommendations for Implementing Change (ERIC). The feasibility of the strategies was evaluated by the proportion of patients who were eligible for encouragement (patients with schizophrenia aged 40, 50, or 60) who received encouragement. We set the goal of providing encouragement to at least 40% of eligible patients at each site. RESULTS: Two public and four private psychiatric hospitals in Okayama and Shimane prefectures participated in this study. Regarding fidelity, all elements of the strategies were conducted as planned. Following the procedures in the guide, each team prepared and provided encouragement according to their own facility and region. Penetration, defined as the proportion of eligible patients who received encouragement, ranged from 33.3 to 100%; five of the six facilities achieved the target proportion. CONCLUSIONS: The provider-level implementation strategies to implement encouragement were feasible in terms of penetration of the intervention assessed at the patient level. The results support the feasibility of proceeding with a future definitive trial of these strategies. TRIAL REGISTRATION: jRCT, jRCT1060220026 . Registered on 06/04/2022.

  DOI PubMed

• Trends in Head and Neck Cancer Mortality from 1999 to 2019 in Japan: An Observational Analysis.

  Tsukasa Higashionna, Keisaku Harada, Akinari Maruo, Takahiro Niimura, Elizabeth Tan, Quynh Thi Vu, Takayoshi Kawabata, Soichiro Ushio, Hirofumi Hamano, Makoto Kajizono, Yoshito Zamami, Keisuke Ishizawa, Ko Harada, Shiro Hinotsu, Mitsunobu R Kano, Hideharu Hagiya, Toshihiro Koyama

  Cancers   15 ( 15 )  2023年07月  [国際誌]

  　概要を見る

  Globally, the numbers of head and neck cancer (HNC) cases and related deaths have recently increased. In Japan, few studies have examined crude or age-adjusted HNC mortality rates. Therefore, this study aimed to determine the trends in crude and age-adjusted mortality rates for HNC per million individuals in Japan from 1999 to 2019. Data on HNC-associated deaths were extracted from the national death certificate database using the International Classification of Diseases, Tenth Revision (n = 156,742). HNC mortality trends were analysed using joinpoint regression models to estimate annual percentage change (APC) and average APC (AAPC). Among men, no significant change was observed in the age-adjusted death rate trend from 1999 to 2014; however, a marked decrease was observed from 2014 to 2019. No changing point was observed in women. Age-adjusted mortality rates continuously decreased over the 21-year period, with an AAPC of -0.7% in men and -0.6% in women. In conclusion, the overall trend in age-adjusted rates of HNC-associated deaths decreased, particularly among men, in the past 5 years. These results will contribute to the formulation of medical policies to develop targeted screening and prevention programmes for HNC in Japan and determine the direction of treatment strategies.

  DOI PubMed

• Increasing disparities in cancer screening among people with severe mental illness during the COVID-19 pandemic.

  Masaki Fujiwara, Yuto Yamada, Taichi Shimazu, Naoki Nakaya, Shiro Hinotsu, Maiko Fujimori, Yosuke Uchitomi, Masatoshi Inagaki

  Schizophrenia research   258   18 - 20  2023年07月  [国際誌]

  DOI PubMed

• A multicenter, retrospective observational study investigating baseline characteristics and clinical outcomes in patients with hormone-sensitive prostate cancer treated with primary androgen deprivation therapy.

  Satoru Taguchi, Mizuki Onozawa, Shiro Hinotsu, Taketo Kawai, Takeshi Mitomi, Satoshi Uno, Haruki Kume

  Japanese journal of clinical oncology   53 ( 10 ) 957 - 965  2023年07月  [国際誌]

  　概要を見る

  OBJECTIVE: This multicenter, retrospective, observational study investigated baseline characteristics and clinical outcomes in patients with hormone-sensitive prostate cancer who received primary androgen deprivation therapy, using Japan Study Group of Prostate Cancer registry data. METHODS: Among patients in the Japan Study Group of Prostate Cancer registry, those who initiated primary androgen deprivation therapy and were aged 20 years or older were enrolled in this study. The primary endpoint was time to disease progression, defined as time from primary androgen deprivation therapy initiation to either prostate-specific antigen or clinical progression. Secondary endpoints included prostate-specific antigen progression-free survival, prostate-specific antigen response (90% or greater reduction from baseline) and distribution of second-line treatment. RESULTS: Of the 2494 patients (goserelin, n = 564; leuprorelin, n = 1148; surgical castration, n = 161; degarelix, n = 621), those who received degarelix had higher prostate-specific antigen levels and Gleason scores and were at a more advanced clinical stage than those receiving goserelin or leuprorelin. The median time to disease progression (identical to the prostate-specific antigen progression-free survival result) was not reached for goserelin and leuprorelin, 52.7 months for surgical castration and 54.0 months for degarelix. Although baseline prostate-specific antigen values in the degarelix cohort were higher than those of the leuprorelin or goserelin cohorts, prostate-specific antigen responses were not different among the three cohorts. Regarding second-line treatment, the largest patient group received degarelix followed by leuprorelin (n = 195). CONCLUSIONS: This study clarified patient characteristics and long-term effectiveness of primary androgen deprivation therapy in real-world clinical practice. Japanese urologists appear to select appropriate primary androgen deprivation therapy based on patient background and tumour characteristics, with degarelix largely reserved for higher risk patients.

  DOI PubMed

全件表示 >>

Misc 【 表示 ／ 非表示 】

Misc 【 表示 ／ 非表示 】

• Late recurrence in patients with non-muscle-invasive bladder cancer after 5-year cancer-free periods.

  Yurie Hirata, Madoka Higuchi, Takahiro Osawa, Shiro Hinotsu, Toru Harabayashi, Tango Mochizuki, Nobuyasu Enami, Osamu Nounaka, Yuichiro Shinno, Hiroshi Kikuchi, Ryuji Matsumoto, Takashige Abe, Sachiyo Murai, Nobuo Shinohara

  International journal of urology : official journal of the Japanese Urological Association ( LIPPINCOTT WILLIAMS & WILKINS )  203 ( 10 ) E1079 - E1080  2022年05月   [ 国際誌 ]

  　概要を見る

  OBJECTIVES: There is no consensus about the follow-up schedule after 5-year cancer-free periods. In this study, we aimed to elucidate the risk factors for the recurrence in patients with non-muscle-invasive bladder cancer who remained cancer free for more than 5 years. METHODS: Data from six Japanese institutions were retrospectively reviewed. Among the patients with non-muscle-invasive bladder cancer who were treated with transurethral resection of bladder tumor between 1990 and 2013, those who had no recurrence for more than 5 years were included in this study. The Kaplan-Meier method and Cox hazards model were used to estimate recurrence-free survival and to determine the pathologic and clinical factors affecting late recurrence. RESULTS: In total, 434 patients were enrolled in this study. Of these patients, 55 patients (12.7%) experienced late recurrence. The median follow-up time was 8.9 years (interquartile range 6.9-11.3 years). Prior history of bladder cancer before the most recent transurethral resection was a significant predictor for late recurrence (hazard ratio 1.99 [95% confidence interval 1.13-3.47], P = 0.019), although other clinical factors including tumor grade, pathologic stage, tumor multiplicity, and current risk classification systems were not associated with late recurrence. CONCLUSIONS: Late recurrence after a long tumor-free period is not rare and it was not predicted by current risk classification systems. Only prior history of bladder cancer was a significant predictor for late recurrence in this study.

  DOI PubMed

• 新規アンドロゲン受容体阻害薬を用いた遠隔転移のない去勢抵抗性前立腺癌(M0CRPC)治療戦略のアップデート-ARAMIS試験をはじめとした新規AR阻害薬第III相試験の最終解析結果を受けて-

  鈴木和浩, 上村博司, 鈴木啓悦, 樋之津史郎, 大家基嗣

  泌尿器外科   33 ( 11 )  2020年

  J-GLOBAL

• Personalized peptide vaccination for castration resistant prostate cancer progressing after docetaxel chemotherapy: A randomized, double-blind, placebo controlled, phase III trial.

  Masanori Noguchi, Kiyohide Fujimoto, Gaku Arai, Hiroji Uemura, Katsuyoshi Hashine, Hiroaki Matsumoto, Satoshi Fukasawa, Hideomi Nakatsu, Atsushi Takenaka, Masato Fujisawa, Hirotsugu Uemura, Seiji Naito, Shin Egawa, Hiroyuki Fujimoto, Shiro Hinotsu, Kyogo Itoh, Yasuo Kohjimoto

  JOURNAL OF CLINICAL ONCOLOGY ( AMER SOC CLINICAL ONCOLOGY )  37 ( 15 )  2019年05月

  研究発表ペーパー・要旨（国際会議）  

  DOI

• ガイドライン・取り扱い規約作成にあたっての連携

  大家 基嗣, 鈴木 和浩, 篠原 信雄, 石塚 修, 樋之津 史郎, 関根 芳岳

  日本泌尿器科学会雑誌 ( (一社)日本泌尿器科学会 )  109 ( Suppl. ) S58 - S59  2018年11月

• 非弁膜症性心房細動患者における医療費に関する研究

  大島 礼子, 野村 和喜, 小山 敏弘, 座間味 義人, 樋之津 史郎, 狩野 光伸

  日本薬学会年会要旨集 ( (公社)日本薬学会 )  138年会 ( 4 ) 185 - 185  2018年03月

全件表示 >>

共同研究・競争的資金等の研究課題 【 表示 ／ 非表示 】

共同研究・競争的資金等の研究課題 【 表示 ／ 非表示 】

• 医療データサイエンスによる高齢者医療の疾病構造に関する臨床疫学研究

  基盤研究(C)

  研究期間:

  2022年04月

  -

  2025年03月

   

  小山 敏広, 萩谷 英大, 座間味 義人, 樋之津 史郎

• 医療ビッグデータの活用による高齢者医療の疾病構造と質評価に関する臨床疫学研究

  基盤研究(C)

  研究期間:

  2019年04月

  -

  2022年03月

   

  小山 敏広, 萩谷 英大, 座間味 義人, 樋之津 史郎, 狩野 光伸

  　研究概要を見る

  本研究は全国民を対象とする医療ビッグデータの活用と臨床疫学的な手法の統合により，高齢者医療の実態を長期的な視点で分析することを目的とした。これまで高齢者を対象に全国民の医療ビッグデータを活用した研究として、対象となりうる疾患を明らかにし、呼吸器感染症のinfluenza感染症、再興感染症のheaptitis C感染症、副作用関連死、アミロイドーシス、サルコイドーシスに関する臨床疫学研究を国際学術誌にそれぞれ発表した。

• ハンセン病医療倫理学の創出に向けた学術的基盤の構築とカリキュラム開発

  基盤研究(B)

  研究期間:

  2018年04月

  -

  2021年03月

   

  近藤 真紀子, 亀岡 智美, 廣畑 聡, 兵藤 好美, 粟屋 剛, 竹田 芳弘, 齋藤 信也, 宮原 信明, 岡 久雄, 本村 昌文, 桑原 敏典, 大浦 まり子, 生田 由加利, 樋之津 史郎, 吉川 あゆみ, 真壁 五月

  　研究概要を見る

  1.「ハンセン病医療倫理学(医療系)」「ハンセン病と人間の尊厳(小中高大学生)」のカリキュラムを構築し、出前授業を積み重ねた。２．講義の充実を図る基礎研究として、治験による眼球摘出事例の臨床倫理、終生隔離が齎した実存的苦悩、他者に理解し辛い知覚障害、ハンセン病者が捉えたコロナパンデミックについて、質的帰納的に分析した。３．ハンセン病者が人生を賭して得た叡智を伝える教材として、「療養所の自然の美しさと祈り」をコンセプトとする書籍を刊行し、加えて、デジタル教材の充実を図った。４．発展の布石として、「ハンセン病倫理研究会」の創設、機関紙「ハンセン病と人間の尊厳」を刊行した。

• 大規模レセプトデータベースを用いた疫学研究結果の妥当性検証手法の確立

  基盤研究(C)

  研究期間:

  2016年04月

  -

  2020年03月

   

  樋之津 史郎, 狩野 光伸

  　研究概要を見る

  レセプトデータをJMDC社から取得した。2005年1月から2017年7月の間に「前立腺がん」と診断された5,767人であった。医療機関数は合計17,001施設で、そのうち85.2%は診療所であった。医薬品処方は合計1,426,115件で、前立腺がん治療に用いられるリュープリン4,288件、カソデックス錠4,220件、ゾラデックス3,155件、オダイン錠1,028件であった。検査の総数は5,225,046件で、クレアチニン91,672件、AST85,736件、ALT85,523件、PSA7,877件であった。 このデータで腎機能、肝機能の有害事象のリスクを推定することができると考えられた。

• メタアナリシスの手法による筋層非浸潤性膀胱癌術後再発リスク分類日本版の作成

  基盤研究(C)

  研究期間:

  2012年04月

  -

  2015年03月

   

  樋之津 史郎, 赤座 英之

  　研究概要を見る

  日本で実施された筋層非浸潤性膀胱癌の再発に関する研究を検索するためのシステムを作成した。データベースはMEDLINE(PuｂMed)と医学中央雑誌（医中誌Web）を用いた。検索結果をダウンロードし、PubMedと医中誌Webのファイルを共通書式で保存するソフトウエアを開発した。このソフトウエアを用いて、論文タイトルに”Superficial”を含む論文と、”Non-muscle invasive”を含む論文をダウンロードしてソフトウエアの作動を検証した。 また、これらファイルを保存するためのクラウドサーバーを準備し、データを保存した。今後、この手法について公表し、開発したソフトウエアを公開する。

全件表示 >>